Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.

Chao MP, Weissman IL, Majeti R.

Curr Opin Immunol. 2012 Apr;24(2):225-32. doi: 10.1016/j.coi.2012.01.010. Epub 2012 Feb 4. Review.

2.

The CD47-SIRPα signalling system: its physiological roles and therapeutic application.

Murata Y, Kotani T, Ohnishi H, Matozaki T.

J Biochem. 2014 Jun;155(6):335-44. doi: 10.1093/jb/mvu017. Epub 2014 Mar 12. Review.

PMID:
24627525
3.

Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by Macrophages.

Lv Z, Bian Z, Shi L, Niu S, Ha B, Tremblay A, Li L, Zhang X, Paluszynski J, Liu M, Zen K, Liu Y.

J Immunol. 2015 Jul 15;195(2):661-71. doi: 10.4049/jimmunol.1401719. Epub 2015 Jun 17.

4.

Targeting the Cancer Biomarker CD47: A Review on the Diverse Mechanisms of the CD47 Pathway in Cancer Treatment.

Zhang L, Huang H.

Anticancer Agents Med Chem. 2016;16(6):658-67. Review.

PMID:
26446381
5.

SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.

Veillette A, Chen J.

Trends Immunol. 2018 Mar;39(3):173-184. doi: 10.1016/j.it.2017.12.005. Epub 2018 Jan 11. Review.

PMID:
29336991
6.

Cancer immunotherapy targeting the CD47/SIRPα axis.

Weiskopf K.

Eur J Cancer. 2017 May;76:100-109. doi: 10.1016/j.ejca.2017.02.013. Epub 2017 Mar 10. Review.

PMID:
28286286
7.

The CD47 pathway is deregulated in human immune thrombocytopenia.

Catani L, Sollazzo D, Ricci F, Polverelli N, Palandri F, Baccarani M, Vianelli N, Lemoli RM.

Exp Hematol. 2011 Apr;39(4):486-94. doi: 10.1016/j.exphem.2010.12.011. Epub 2011 Jan 4.

PMID:
21211546
8.

SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.

Chen J, Zhong MC, Guo H, Davidson D, Mishel S, Lu Y, Rhee I, Pérez-Quintero LA, Zhang S, Cruz-Munoz ME, Wu N, Vinh DC, Sinha M, Calderon V, Lowell CA, Danska JS, Veillette A.

Nature. 2017 Apr 27;544(7651):493-497. doi: 10.1038/nature22076. Epub 2017 Apr 19.

9.

Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels.

Tsai RK, Rodriguez PL, Discher DE.

Blood Cells Mol Dis. 2010 Jun 15;45(1):67-74. doi: 10.1016/j.bcmd.2010.02.016. Epub 2010 Mar 17.

10.

CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.

Murata Y, Saito Y, Kotani T, Matozaki T.

Cancer Sci. 2018 Aug;109(8):2349-2357. doi: 10.1111/cas.13663. Epub 2018 Jul 4. Review.

11.

"Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.

Ho CC, Guo N, Sockolosky JT, Ring AM, Weiskopf K, Özkan E, Mori Y, Weissman IL, Garcia KC.

J Biol Chem. 2015 May 15;290(20):12650-63. doi: 10.1074/jbc.M115.648220. Epub 2015 Apr 2.

12.

High-Affinity SIRPα Variants Potentiate Antibody Therapy Efficacy.

[No authors listed]

Cancer Discov. 2013 Jul;3(7):716. doi: 10.1158/2159-8290.CD-RW2013-124. Epub 2013 Jun 6.

13.

CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.

Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M, Matozaki T, Kraal G, Birnbaum D, van Elsas A, Kuijpers TW, Bertucci F, van den Berg TK.

Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18342-7. doi: 10.1073/pnas.1106550108. Epub 2011 Oct 31.

14.

The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.

Barclay AN, Van den Berg TK.

Annu Rev Immunol. 2014;32:25-50. doi: 10.1146/annurev-immunol-032713-120142. Epub 2013 Nov 6. Review.

PMID:
24215318
15.

Soluble extracellular domains of human SIRPα and CD47 expressed in Escherichia coli enhances the phagocytosis of leukemia cells by macrophages in vitro.

Lin Y, Yan XQ, Yang F, Yang XW, Jiang X, Zhao XC, Zhu BK, Liu L, Qin HY, Liang YM, Han H.

Protein Expr Purif. 2012 Sep;85(1):109-16. doi: 10.1016/j.pep.2012.07.002. Epub 2012 Jul 17.

PMID:
22813925
16.

The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.

Matlung HL, Szilagyi K, Barclay NA, van den Berg TK.

Immunol Rev. 2017 Mar;276(1):145-164. doi: 10.1111/imr.12527. Review.

PMID:
28258703
17.

Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages.

Ide K, Wang H, Tahara H, Liu J, Wang X, Asahara T, Sykes M, Yang YG, Ohdan H.

Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5062-6. Epub 2007 Mar 12.

18.

[Role of CD47 in hematologic malignancies].

Su GH, Zhao YL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Dec;21(6):1631-4. doi: 10.7534/j.issn.1009-2137.2013.06.050. Review. Chinese.

PMID:
24370062
19.

Innate immune 'self' recognition: a role for CD47-SIRPalpha interactions in hematopoietic stem cell transplantation.

van den Berg TK, van der Schoot CE.

Trends Immunol. 2008 May;29(5):203-6. doi: 10.1016/j.it.2008.02.004. Epub 2008 Apr 3. Review.

PMID:
18394962
20.

CD47 functions as a molecular switch for erythrocyte phagocytosis.

Burger P, Hilarius-Stokman P, de Korte D, van den Berg TK, van Bruggen R.

Blood. 2012 Jun 7;119(23):5512-21. doi: 10.1182/blood-2011-10-386805. Epub 2012 Mar 16.

Supplemental Content

Support Center